Investors have poured billions into using artificial intelligence to discover new drugs, and 2026 is the first real test of whether AI-designed medicines actually helps patients. The boom has genuinely transformed the search for molecules — but that was never the costly, failure-prone part of making a medicine, and there AI has so far had little to add. Capital, and the public subsidies have not yet priced the difference, writes Michael A. Santoro.

In February, the Federal Trade Commission settled with pharmaceutical benefits manager (PBM) Express Scripts. The FTC had sued Express Scripts and two other large PBMs under the long dormant Section 5 of the FTC Act, which targets “unfair methods of competition.” The settlement suggests that the FTC may succeed in addressing the convoluted contracts between PBMs, drug manufacturers, health insurers, and employers that drive up drug prices for Americans. It also opens unchartered territory for antitrust enforcement and the limits of Section 5, argue Fiona Scott Morton and Mariah Smith.

In new research, Renuka Diwan, Paul Eliason, Riley League, Ryan C. McDevitt, James W. Roberts, and Jetson Leder-Luis investigate how Medicare’s shift to a competitive bidding system to reduce prices has inadvertently shifted market share to fraudulent suppliers.

Antitrust authorities increasingly assess mergers through the lens of innovation, particularly in research-intensive sectors such as pharmaceuticals. In new research, Carmine Ornaghi and Lorenzo Cassi show how mergers disrupt human capital and reduce innovation in what they call manslaughter acquisitions.

Microsoft CEO Satya Nadella’s argument that businesses need to be able to easily switch between artificial intelligence models is correct but elides the fact,...

In new research, Vishavdeep Sharma and Krishnendu Ghosh Dastidar analyze corporate corruption through the lens of market competition. Firms often bribe officials to block rivals from entering their markets, and their incentive to do so depends less on how competitive a market is than on what kind of competition it has.

The European Union’s draft Merger Guidelines strengthen competition enforcement by acknowledging the potential harms of market concentration to society, including worker bargaining power and more vulnerable democratic institutions. However, Max von Thun and Claire Lavin argue that this progress is undermined by the introduction of a bias for scale and efficiency loopholes, which give large corporations more paths to complete a merger.

In new research, Grace Fan, Trung Nguyen, and Xi Wu show how improvements in government data transparency and disclosure through the public rollout of the Environmental Protection Agency’s Environmental Justice Screening and Mapping Tool enabled civil society to identify and hold polluters responsible and improve overall environmental justice.